Samsa is right- why sell off ANDA to another competitor. That would not make good business sense.
Very good points. Have you sent them to investor relations and asked why they are potentially not being treated fairly when compared to other companies?
I agree it might take time. Short covering could help PPS a little but for sustained support they will need a couple of solid quarters and hopefully a dividend increase. I am not convinced the special divy is the best idea and am not believing for a minute it will happen. Put that money to work in some new loans or by back shares below NAV with that money.
Very good point. If the approved and on the market doses are being grandfathered, why not the tentatively approved doses?
The market has spoken! Hopefully we see PSEC continue to make progress. I in particular am liking how the NAV increased slightly. Good luck PSEC longs who have held on and not given up.
Thank you for looking into these things and sharing your info! Great job.
Interim Analyses in Clinical Trials: Why Do We Plan Them?
Sophie D. Fosså and
This is informative.
From the way I am reading your post, they read out early but was the read out a planned interim result or done simply because the results were so good? What does not make sense is if the results were so good, why would they not try to release early?
Good question. I think the answer Paris received from David Haen suggests that because the primary endpoint is PFS, collecting enough data for PFS will take that long. The question I have for you is are interim looks built into clinical studies that have OS as a primary endpoint and the interim result is the PFS as those numbers can be obtained much earlier than final OS numbers. Does this make sense to everyone? I'd like to hear other opinions here.
My guess is PFS data comes quicker than OS data. Remember last year when we kept waiting and waiting for OS data when PFS had been available for sometime. I think the point he is trying to make is it will take that long to get the PFS data. Hopefully it will take even longer to get the PFS data with dose until progression. I can see how some may say this is them just trying to by time before they announce poor trial results but I am hoping it is just how long it will take.
Feuerstein Ratain rule is AF's little claim to fame. It is nothing more than a restatement of the obvious.... Bottom line, cancer stocks with higher market caps are more likely to gain FDA approval... It is nothing more than that! Don't let these idiots say it is some great theorem the omnipotent Feuerstein discovered, as it is not!
Don't feed AF's little trolls... They don't even deserve the time of day. You said it all, he is alleged journalist who writes articles to benefit himself and his handlers!
Not sure. Might have something to do how he was called out for pumping when he has a position and bashing when he wants it lower... Very repeatable pattern with this trader.
Yep, I am starting to have quite a large stake too. Good thing is the shares I have added now were in low $2's and last time about $2.30. If no serious setbacks, I do not see how this does not work out.
By free cash I meant money in my stock accounts that wasn't currently invested. Was thinking of using this on oil stocks but the outlook on those just keeps getting worse...